Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05948826 · ClinicalTrials.gov registry record · Phase 1
First in Human Study of TORL-3-600 in Participants With Advanced Cancer
A Phase 1 study of Colorectal Cancer and Advanced Solid Tumor, sponsored by TORL Biotherapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 9
- Study locations
NCT05948826 is a Phase 1 study of Colorectal Cancer and Advanced Solid Tumor that is active but no longer recruiting, run by TORL Biotherapeutics. The registered enrollment target is 70 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (95% lower). The trial reports 9 study locations across 8 states.
The verdict
NCT05948826, a Phase 1 study of Colorectal Cancer and Advanced Solid Tumor, is active but no longer recruiting, sponsored by TORL Biotherapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 9
- Study locations
Study Summary
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-3-600 in patients with advanced cancer
Conditions Studied
Interventions
- DRUG TORL-3-600
Study Locations (9)
California
- Providence Medical Foundation - Fullerton
- UCLA - JCCC Clinical Research Unit - Los Angeles
Colorado
- Sarah Cannon Research Institute - Denver
Indiana
- Fort Wayne Medical Oncology and Hematology Inc. - Fort Wayne
Missouri
- Washington University School of Medicine-Siteman Cancer Center - St Louis
Tennessee
- Sarah Cannon Research Institute-Tennessee - Nashville
Texas
- Mary Crowley Cancer Research - Dallas
Ontario
- University Health Network, Princess Margaret Cancer Centre - Toronto
Quebec
- McGill University Health Centre - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2023-09-29 |
| Est. Completion | 2026-09-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05948826
The ClinicalTrials.gov registry entry for NCT05948826 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (95% lower). The listed sponsor is TORL Biotherapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which TORL-3-600 is the first listed.
NCT05948826 reports 9 study locations spanning 8 distinct geographic areas - top geographies include California, Colorado, Indiana.
Frequently Asked Questions
What is clinical trial NCT05948826 about?
NCT05948826 is a clinical study titled "First in Human Study of TORL-3-600 in Participants With Advanced Cancer". This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-3-600 in patients with advanced cancer
What is the current status of trial NCT05948826?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2023-09-29. Estimated completion is 2026-09-15.
What conditions does trial NCT05948826 study?
This clinical trial studies the following conditions: Colorectal Cancer, Advanced Solid Tumor.
What interventions are being tested in trial NCT05948826?
The interventions under investigation include: TORL-3-600 (DRUG).
Who is sponsoring clinical trial NCT05948826?
This trial is sponsored by TORL Biotherapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05948826 being conducted?
This trial has 9 study locations across California, Colorado, Indiana, Missouri, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.